胃癌分子分型及免疫靶向治疗  

Molecular classification and immune target therapy of gastric cancer

作　　者：宋锦添 杨建伟[1] 许春伟[2] SONG Jintian YANG Jianwei XU Chunwei(Department of Gastrointestinal Oncology, Fujian Provincial Cancer Hospital of Fujian Medical University, Fuzhou 350014 Department of Pathology, Affiliated Hospital of Academy of Military Medical Science, Beijing 100071, China)

机构地区：[1]福建医科大学附属福建省肿瘤医院消化道肿瘤内科,福州350014 [2]军事医学科学院附属医院病理科,北京100071

出　　处：《临床与病理杂志》2017年第2期435-442,共8页Journal of Clinical and Pathological Research

基　　金：国家临床重点专科建设项目(2013);军事医学科学院附属医院创新科研基金(ZH-2014-10)~~

摘　　要：目前曲妥珠单抗、ramucirumab是已经被FDA获批用于晚期胃癌的靶向药物。同时仍正在研究的靶点包括EGFR、PI3K蛋白激酶B/哺乳动物雷帕霉素靶点(m TOR)途径、c-MET以及免疫检查点抑制剂。本综述主要讨论晚期胃癌的分子分型和目前已经用于晚期胃癌的靶向药物,同时讨论临床试验阶段的免疫靶向药物。At present, trastuzumab and ramucirumab has been approved by the FDA for advanced gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met and immune checkpoint inhibition. We focuses on molecular classification of advanced gastric cancer, targeted drugs which have used for advanced gastric cancer and the immune targeted drug clinical trials.

关 键 词：胃癌 分子分型 靶向治疗 免疫靶向药物 

分 类 号：R735.2[医药卫生—肿瘤]